Total medical devices industry venture financing deals in July 2020 worth $1.2bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 85.7% over the previous month and a rise of 77.2% when compared with the last 12-month average of $677.17m.
The US held a 66.7% share of the global medical devices industry venture financing deal value that totalled $1.8bn in July 2020.
In terms of deal activity, the US recorded 51 deals during July 2020, marking an increase of 18.6% over the previous month and a drop of 12.1% over the 12-month average.
The US medical devices industry venture financing deals in July 2020: Top deals
The top five medical devices industry venture financing deals accounted for 55.1% of the overall value during July 2020.
The combined value of the top five medical devices venture financing deals stood at $661m, against the overall value of $1.2bn recorded for the month.
The top five medical devices industry deals of July 2020 tracked by GlobalData were:
1) Bain Capital Life Sciences, Brown Advisory, Casdin Capital, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Springs Capital Management, Sands Capital Management, Section 32 and T Rowe Price Associates’ $257m venture financing of Thrive Earlier Detection
2) The $137m venture financing of Preventice by Boston Scientific, Merck Global Health Innovation Fund, Novo Holdings, Samsung Catalyst Fund and Vivo Capital
3) BlackRock, Connecticut Innovations, Decheng Capital, Deerfield ManagementLP, Moore Strategic Ventures, Oak HC/FT Partners, Section 32 and The Blackstone Group’s $121m venture financing of Mount Sinai Genomics
4) The $75m venture financing of Doctor On Demand by General Atlantic
5) Charles and Helen Schwab Foundation, Gilde Healthcare Partners, Longitude Capital Management Co, Nan Fung Life Sciences and New Enterprise Associates’ venture financing of Eargo for $71m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.